Platinum-resistant Ovarian Cancer

Oncology
7
Pipeline Programs
7
Companies
7
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
1
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

ImmunityBio
ImmunityBioSAN DIEGO, CA
1 program
1
GemcitabinePhase 21 trial
Active Trials
NCT06710288Recruiting20Est. May 2027
Laekna Therapeutics
Laekna TherapeuticsChina - Shanghai
1 program
1
PaclitaxelPhase 21 trial
Active Trials
NCT04374630CompletedEst. Jun 2024
InxMed
InxMedChina - Beijing
1 program
1
IN10018 in combination with PLDPhase 1/21 trial
Active Trials
NCT05551507Recruiting150Est. Dec 2025
Nurix Therapeutics
Nurix TherapeuticsBRISBANE, CA
1 program
1
Drug Product De-TIL-0255Phase 11 trial
Active Trials
NCT05107739TerminatedEst. May 2023
Stemline Therapeutics
1 program
1
MEN2501Phase 11 trial
Active Trials
NCT07226427Recruiting100Est. Jun 2028
iBio
iBioNEW YORK, NY
1 program
1
PHI-101 administrationPhase 11 trial
Active Trials
NCT04678102UnknownEst. Dec 2023
Shattuck Labs
Shattuck LabsAUSTIN, TX
1 program
1
Pegylated Liposomal Doxorubicin + SL-172154Phase 11 trial
Active Trials
NCT05483933CompletedEst. Feb 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
ImmunityBioGemcitabine
Laekna TherapeuticsPaclitaxel
InxMedIN10018 in combination with PLD
Stemline TherapeuticsMEN2501
Shattuck LabsPegylated Liposomal Doxorubicin + SL-172154
Nurix TherapeuticsDrug Product De-TIL-0255
iBioPHI-101 administration

Clinical Trials (7)

Total enrollment: 270 patients across 7 trials

NCT06710288ImmunityBioGemcitabine

A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer

Start: Nov 2024Est. completion: May 202720 patients
Phase 2Recruiting
NCT04374630Laekna TherapeuticsPaclitaxel

Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian

Start: Jun 2020Est. completion: Jun 2024
Phase 2Completed
NCT05551507InxMedIN10018 in combination with PLD

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

Start: Jul 2020Est. completion: Dec 2025150 patients
Phase 1/2Recruiting
NCT07226427Stemline TherapeuticsMEN2501

A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer

Start: Nov 2025Est. completion: Jun 2028100 patients
Phase 1Recruiting
NCT05483933Shattuck LabsPegylated Liposomal Doxorubicin + SL-172154

Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers

Start: Aug 2022Est. completion: Feb 2025
Phase 1Completed
NCT05107739Nurix TherapeuticsDrug Product De-TIL-0255

A Study of DeTIL-0255 in Adults With Advanced Malignancies

Start: Dec 2021Est. completion: May 2023
Phase 1Terminated
NCT04678102iBioPHI-101 administration

Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)

Start: Dec 2020Est. completion: Dec 2023
Phase 1Unknown

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 270 patients
7 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)